A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

About

Brief Summary

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
PRE21-007357
Category
Hematology-Oncology
Oncology
Principal Investigator
Randolph Hecht
Contact
Kimberly Kelly
Location
  • TRIO-US - Bakersfield
  • TRIO-US - Redondo Beach
  • TRIO-US - Sylmar
  • TRIO-US - Whittier